1. Home
  2. WEAV vs RGNX Comparison

WEAV vs RGNX Comparison

Compare WEAV & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Weave Communications Inc.

WEAV

Weave Communications Inc.

HOLD

Current Price

$4.75

Market Cap

487.7M

Sector

Technology

ML Signal

HOLD

Logo REGENXBIO Inc.

RGNX

REGENXBIO Inc.

HOLD

Current Price

$8.37

Market Cap

418.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WEAV
RGNX
Founded
2011
2008
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
487.7M
418.1M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
WEAV
RGNX
Price
$4.75
$8.37
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
8
Target Price
$11.00
$28.75
AVG Volume (30 Days)
1.7M
791.9K
Earning Date
05-04-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
7.50
18.08
EPS
N/A
N/A
Revenue
$239,024,000.00
$10,393,000.00
Revenue This Year
$17.20
$50.05
Revenue Next Year
$13.74
$23.31
P/E Ratio
N/A
N/A
Revenue Growth
16.99
126.48
52 Week Low
$4.60
$5.04
52 Week High
$12.17
$16.19

Technical Indicators

Market Signals
Indicator
WEAV
RGNX
Relative Strength Index (RSI) 33.48 41.72
Support Level N/A $7.83
Resistance Level $7.31 $9.28
Average True Range (ATR) 0.26 0.51
MACD 0.01 0.03
Stochastic Oscillator 15.18 13.64

Price Performance

Historical Comparison
WEAV
RGNX

About WEAV Weave Communications Inc.

Weave Communications Inc is a customer experience and payments software platform tailored for SMB healthcare businesses, that revolutionizes patient interaction from initial contact to billing. It integrates diverse workflows into a unified solution, minimizing manual tasks and maximizing patient engagement. Weave democratizes enterprise-level communication tools, simplifying them for SMBs in a singular platform. Offering varied communication channels, appointment scheduling, payment processing, and more, enhances practitioner-patient relationships and optimizes practice operations. The company has a singular operating segment and revenue from subscription services.

About RGNX REGENXBIO Inc.

Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.

Share on Social Networks: